IGC Pharma (IGC) Income from Continuing Operations (2010 - 2025)
IGC Pharma (IGC) posted quarterly Income from Continuing Operations of 1821000.0 for Q3 2025, down 6.06% year-over-year from 1938411.04 in Q3 2024, and down 13.88% quarter-over-quarter from 1599000.0 in Q2 2025.
IGC Pharma (IGC) Income from Continuing Operations (2010 - 2025) Analysis & Trends
IGC Pharma (IGC) has reported Income from Continuing Operations for 16 consecutive years, with 1821000.0 the latest figure, recorded in Q3 2025.
- In Q3 2025, Income from Continuing Operations fell 6.06% year-over-year to 1821000.0; the TTM figure through Sep 2025 stood at 6447000.0 (up 54.09% YoY), while the FY2026 annual figure was 2402000.0, up 50.12% from the prior year.
- Income from Continuing Operations fell to 1821000.0 in Q3 2025 per IGC's latest filing, from 1599000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 1198000.0 in Q1 2025 and bottomed at 6553000.0 in Q1 2022.
- Historically, Income from Continuing Operations has averaged 2743263.16 across 5 years, with a median of 2378000.0 in 2024.
- Annual changes were most pronounced in 2021 — Income from Continuing Operations plunged 4173.91% — and 2023, when it soared 75.37%.
- IGC Pharma's Income from Continuing Operations stood at 2381000.0 in 2021, then gained by 5.54% to 2249000.0 in 2022, then slumped by 148.51% to 5589000.0 in 2023, then surged by 67.28% to 1829000.0 in 2024, then climbed by 0.44% to 1821000.0 in 2025.
- Business Quant data shows IGC's Income from Continuing Operations at 1821000.0 in Q3 2025, 1599000.0 in Q2 2025, and 1198000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 164.49 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -13.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 81.49 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -174.37 Mn |
| 10 | IGC Pharma | 27.20 Mn | 26.94 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -1.82 Mn |
| Jun 30, 2025 | -1.60 Mn |
| Mar 31, 2025 | -1.20 Mn |
| Dec 31, 2024 | -1.83 Mn |
| Sep 30, 2024 | -1.72 Mn |
| Jun 30, 2024 | -2.38 Mn |
| Mar 31, 2024 | -4.36 Mn |
| Dec 31, 2023 | -5.59 Mn |
| Sep 30, 2023 | -2.45 Mn |
| Jun 30, 2023 | -2.08 Mn |
| Mar 31, 2023 | -1.61 Mn |
| Dec 31, 2022 | -2.25 Mn |
| Sep 30, 2022 | -2.44 Mn |
| Jun 30, 2022 | -2.79 Mn |
| Mar 31, 2022 | -6.55 Mn |
| Dec 31, 2021 | -2.38 Mn |
| Sep 30, 2021 | -4.34 Mn |
| Jun 30, 2021 | -1.79 Mn |
| Mar 31, 2021 | -2.95 Mn |
| Dec 31, 2020 | -2.32 Mn |